位置:首页 > 蛋白库 > TLR4_PANPA
TLR4_PANPA
ID   TLR4_PANPA              Reviewed;         839 AA.
AC   Q9TTN0;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   25-MAY-2022, entry version 122.
DE   RecName: Full=Toll-like receptor 4;
DE   AltName: CD_antigen=CD284;
DE   Flags: Precursor;
GN   Name=TLR4;
OS   Pan paniscus (Pygmy chimpanzee) (Bonobo).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Pan.
OX   NCBI_TaxID=9597;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11104518; DOI=10.1186/gb-2000-1-1-research002;
RA   Smirnova I., Poltorak A., Chan E.K.L., McBride C., Beutler B.;
RT   "Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus
RT   (TLR4).";
RL   Genome Biol. 1:RESEARCH002.1-RESEARCH002.10(2000).
CC   -!- FUNCTION: Cooperates with LY96 and CD14 to mediate the innate immune
CC       response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP
CC       and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the
CC       inflammatory response (By similarity). Also involved in LPS-independent
CC       inflammatory responses triggered by free fatty acids, such as
CC       palmitate. In complex with TLR6, promotes sterile inflammation in
CC       monocytes/macrophages in response to oxidized low-density lipoprotein
CC       (oxLDL) or amyloid-beta 42. In this context, the initial signal is
CC       provided by oxLDL- or amyloid-beta 42-binding to CD36. This event
CC       induces the formation of a heterodimer of TLR4 and TLR6, which is
CC       rapidly internalized and triggers inflammatory response, leading to the
CC       NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via
CC       MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling
CC       pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-))
CC       and mediates the cytokine release induced by LDL(-) (By similarity).
CC       Activated by the signaling pathway regulator NMI which acts as damage-
CC       associated molecular patterns (DAMPs) in response to cell injury or
CC       pathogen invasion, therefore promoting nuclear factor NF-kappa-B
CC       activation (By similarity). {ECO:0000250|UniProtKB:O00206,
CC       ECO:0000250|UniProtKB:Q9QUK6}.
CC   -!- SUBUNIT: Belongs to the lipopolysaccharide (LPS) receptor, a multi-
CC       protein complex containing at least CD14, LY96 and TLR4. Binding to
CC       bacterial LPS leads to homodimerization. Interacts with LY96 via the
CC       extracellular domain. Interacts with MYD88 and TIRAP via their
CC       respective TIR domains. Interacts with NOX4. Interacts with CNPY3 and
CC       HSP90B1; this interaction is required for proper folding in the
CC       endoplasmic reticulum. Interacts with MAP3K21; this interaction leads
CC       to negative regulation of TLR4 signaling. Interacts with CD36,
CC       following CD36 stimulation by oxLDL or amyloid-beta 42, and forms a
CC       heterodimer with TLR6. The trimeric complex is internalized and
CC       triggers inflammatory response. LYN kinase activity facilitates TLR4-
CC       TLR6 heterodimerization and signal initiation. Interacts with TICAM1 in
CC       response to LPS in a WDFY1-dependent manner. Interacts with WDFY1 in
CC       response to LPS. Interacts with SMPDL3B. Interacts with CEACAM1; upon
CC       lipopolysaccharide stimulation, forms a complex including TLR4 and the
CC       phosphorylated form of SYK and CEACAM1, which in turn, recruits PTPN6
CC       that dephosphorylates SYK, reducing the production of reactive oxygen
CC       species (ROS) and lysosome disruption, which in turn, reduces the
CC       activity of the inflammasome. Interacts with RFTN1; the interaction
CC       occurs in response to lipopolysaccharide stimulation. Interacts with
CC       SCIMP; the interaction occurs in response to lipopolysaccharide
CC       stimulation and is enhanced by phosphorylation of SCIMP by LYN (By
CC       similarity). This interaction facilitates the phosphorylation of TLR4
CC       by LYN which elicits a selective cytokine response in macrophages (By
CC       similarity). Interacts with TRAF3IP3 (By similarity). Interacts with
CC       TREM1; this interaction enhances TLR4-mediated inflammatory response
CC       (By similarity). {ECO:0000250|UniProtKB:O00206,
CC       ECO:0000250|UniProtKB:Q9QUK6}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:O00206};
CC       Single-pass type I membrane protein {ECO:0000250|UniProtKB:O00206}.
CC       Early endosome {ECO:0000250|UniProtKB:O00206}. Cell projection, ruffle
CC       {ECO:0000250|UniProtKB:Q9QUK6}. Note=Upon complex formation with CD36
CC       and TLR6, internalized through dynamin-dependent endocytosis.
CC       Colocalizes with RFTN1 at cell membrane and then together with RFTN1
CC       moves to endosomes, upon lipopolysaccharide stimulation.
CC       {ECO:0000250|UniProtKB:O00206}.
CC   -!- DOMAIN: The TIR domain mediates interaction with NOX4. {ECO:0000250}.
CC   -!- PTM: Phosphorylated on tyrosine residues by LYN after binding
CC       lipopolysaccharide. {ECO:0000250|UniProtKB:Q9QUK6}.
CC   -!- SIMILARITY: Belongs to the Toll-like receptor family. {ECO:0000305}.
CC   -!- CAUTION: In some plant proteins and in human SARM1, the TIR domain has
CC       NAD(+) hydrolase (NADase) activity (By similarity). However, despite
CC       the presence of the catalytic Asp residue, the isolated TIR domain of
CC       human TLR4 lacks NADase activity (By similarity). Based on this, it is
CC       unlikely that Toll-like receptors have NADase activity.
CC       {ECO:0000250|UniProtKB:O00206, ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF179220; AAF05320.1; -; Genomic_DNA.
DR   EMBL; AF179218; AAF05320.1; JOINED; Genomic_DNA.
DR   EMBL; AF179219; AAF05320.1; JOINED; Genomic_DNA.
DR   AlphaFoldDB; Q9TTN0; -.
DR   SMR; Q9TTN0; -.
DR   STRING; 9597.NP_001266152.1; -.
DR   eggNOG; KOG4641; Eukaryota.
DR   Proteomes; UP000240080; Unplaced.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0046696; C:lipopolysaccharide receptor complex; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell.
DR   GO; GO:0001875; F:lipopolysaccharide immune receptor activity; ISS:UniProtKB.
DR   GO; GO:0050135; F:NAD(P)+ nucleosidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:InterPro.
DR   GO; GO:0032497; P:detection of lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0042116; P:macrophage activation; ISS:UniProtKB.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISS:UniProtKB.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; IEA:InterPro.
DR   Gene3D; 3.40.50.10140; -; 1.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000157; TIR_dom.
DR   InterPro; IPR017241; Toll-like_receptor.
DR   InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR   PANTHER; PTHR24365; PTHR24365; 1.
DR   Pfam; PF13855; LRR_8; 3.
DR   Pfam; PF01582; TIR; 1.
DR   PIRSF; PIRSF037595; Toll-like_receptor; 1.
DR   SMART; SM00369; LRR_TYP; 11.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00255; TIR; 1.
DR   SUPFAM; SSF52200; SSF52200; 1.
DR   PROSITE; PS51450; LRR; 11.
DR   PROSITE; PS50104; TIR; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Cell projection; Disulfide bond; Endosome; Glycoprotein;
KW   Immunity; Inflammatory response; Innate immunity; Leucine-rich repeat;
KW   Membrane; NAD; Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..839
FT                   /note="Toll-like receptor 4"
FT                   /id="PRO_0000034724"
FT   TOPO_DOM        24..631
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        632..652
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        653..839
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          55..76
FT                   /note="LRR 1"
FT   REPEAT          79..100
FT                   /note="LRR 2"
FT   REPEAT          103..124
FT                   /note="LRR 3"
FT   REPEAT          127..148
FT                   /note="LRR 4"
FT   REPEAT          151..172
FT                   /note="LRR 5"
FT   REPEAT          176..199
FT                   /note="LRR 6"
FT   REPEAT          205..225
FT                   /note="LRR 7"
FT   REPEAT          227..247
FT                   /note="LRR 8"
FT   REPEAT          331..351
FT                   /note="LRR 9"
FT   REPEAT          352..373
FT                   /note="LRR 10"
FT   REPEAT          374..394
FT                   /note="LRR 11"
FT   REPEAT          400..422
FT                   /note="LRR 12"
FT   REPEAT          423..444
FT                   /note="LRR 13"
FT   REPEAT          448..456
FT                   /note="LRR 14"
FT   REPEAT          472..495
FT                   /note="LRR 15"
FT   REPEAT          497..518
FT                   /note="LRR 16"
FT   REPEAT          521..542
FT                   /note="LRR 17"
FT   REPEAT          545..565
FT                   /note="LRR 18"
FT   DOMAIN          579..629
FT                   /note="LRRCT"
FT   DOMAIN          672..815
FT                   /note="TIR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT   CARBOHYD        35
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        173
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        205
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        282
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        309
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        497
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        526
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        575
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        624
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        630
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        29..40
FT                   /evidence="ECO:0000250"
FT   DISULFID        281..306
FT                   /evidence="ECO:0000250"
FT   DISULFID        390..391
FT                   /evidence="ECO:0000250"
FT   DISULFID        583..609
FT                   /evidence="ECO:0000250"
FT   DISULFID        585..627
FT                   /evidence="ECO:0000250"
SQ   SEQUENCE   839 AA;  95638 MW;  3B328C5682127D37 CRC64;
     MMSASRLAGT LIPAMAFLSC VRPESWEPCV EVVPNITYQC MELNFYKIPD NLPFSTKNLD
     LSFNPLRHLG SYSFFSFPEL QVLDLSRCEI QTIEDGAYQS LSHLSTLILT GNPIQSLALG
     AFSGLSSLQK LVAVETNLAS LENFPIGHLK TLKELNVAHN LIQSFKLPEY FSNLTNLEHL
     DLSSNKIQSI YCTDLRVLHQ MPLLNLSLDL SLNPMNFIQP GAFKEIRLHK LTLRNNFDSL
     NVMKTCIQGL AGLEVHRLVL GEFRNEGNLE KFDKSALEGL CNLTIEEFRL AYLDYYLDDI
     IDLFNCLTNV SSFSLVSVTI KSVKDFSYNF GWQHLELVNC KFGQFPTLKL KSLKRLTFTS
     NKGGNAFSEV DLPSLEFLDL SRNGLSFKGC CSQSDFGTTS LKYLDLSFNG VITMSSNFLG
     LEQLEHLDFQ HSNLKQMSEF SVFLSLRNLI YLDISHTHTR VAFNGIFNGL SSLEVLKMAG
     NSFQENFLPD IFTELRNLTF LDLSQCQLEQ LSPTAFNSLS SLQVLNMSHN NFFSLDTFPY
     KCLNSLQVLD YSLNHIMTSK KQELQHFPSS LAFLNLTQND FACTCEHQSF LQWIKDQRQL
     LVEVERMECA TPSDKQGMPV LSLNITCQMN KTIIGVSVLS VLVVSVVAVL VYKFYFHLML
     LAGCIKYGRG ENIYDAFVIY SSQDEDWVRN ELVKNLEEGV PPFQLCLHYR DFIPGVAIAA
     NIIHEGFHKS RKVIVVVSQH FIQSRWCIFE YEIAQTWQFL SSRAGIIFIV LQKVEKTLLR
     RQVELYRLLS RNTYLEWEDS VLGRHIFWRR LRKALLDGKS WNPEGTVGTG CNWQEATSI
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2025